Cardiogeni Plc (CGNI)

Sell: 3.00p|Buy: 10.00p|Change: 0 (0%)

Open

7.00p

Previous close

7.00p

Trade high

3.00p

Volume

198,334

ISIN

GB00BTBLFC12

This share can be held in a Dealing account Stocks and shares ISA Lifetime ISA JISA SIPP

This investment is listed on the Aquis Stock Exchange. Investments on this market tend to be higher risk and have lower liquidity, meaning they can be harder to buy or sell, and their prices may be more volatile. Before investing, make sure you understand the risks of investing.

Share price

Performance

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann

	Total return (%)
Cardiogeni Plc	0
More...

Company profile

Cardiogeni PLC is developing a new class of life-saving cellular medicines. The Group's platform technology enables the creation of (living) cells that are engineered with a specific therapeutic function. Its product, CLXR-001, is a patented engineered cellular medicine to treat heart failure patients which is administered during coronary artery bypass grafting surgery.

Sector

Healthcare

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.